Development of an multicriteria decision analysis framework for rare disease reimbursement prioritization in Malaysia.

IF 2.6 4区 医学 Q2 HEALTH CARE SCIENCES & SERVICES International Journal of Technology Assessment in Health Care Pub Date : 2024-09-04 DOI:10.1017/S026646232400031X
Ku N Ku Abd Rahim, Nurkhodrulnada Muhammad Lattepi, Roza Sarimin, Sze Shir Foo, Syaqirah Akmal, Sit Wai Lee, Izzuna Mudla Mohamed Ghazali
{"title":"Development of an multicriteria decision analysis framework for rare disease reimbursement prioritization in Malaysia.","authors":"Ku N Ku Abd Rahim, Nurkhodrulnada Muhammad Lattepi, Roza Sarimin, Sze Shir Foo, Syaqirah Akmal, Sit Wai Lee, Izzuna Mudla Mohamed Ghazali","doi":"10.1017/S026646232400031X","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Rare diseases (RD)-related policies have received significant attention due to the pressing medical requirements associated with these medical conditions and the substantial impact and treatments they may have on healthcare budgets. Nevertheless, policymakers frequently encounter difficulties in managing issues concerning resource allocation and prioritization within this population. Realizing the need to address such problems, this study was conducted to develop a framework based on the multicriteria decision analysis to improve RD reimbursement prioritization in Malaysia.</p><p><strong>Methods: </strong>Primarily, a scoping review was performed to identify the methods and criteria used for the reimbursement of RD treatment, followed by strategic stakeholder engagement and a deliberative process on determining the best approach for the framework, including criteria identification, elicitation of weights, and a pilot assessment using the framework.</p><p><strong>Results: </strong>The findings reflected the priorities and perspectives of the stakeholders, which identified eight key criteria and their associated weights, namely effectiveness (19.6 percent), disease severity (15.6 percent), safety (14.2 percent), access to treatment (12.6 percent), economic consideration (12.2 percent), type of therapeutic treatment (11.5 percent), availability of alternatives (8.3 percent), and population group (6 percent).</p><p><strong>Conclusions: </strong>In summary, the developed framework was well-accepted by the Rare Disease Committee, which will be applied as part of the committee deliberation for transparent and equitable decision making on fund allocation and reimbursement of orphan and RD treatment in Malaysia.</p>","PeriodicalId":14467,"journal":{"name":"International Journal of Technology Assessment in Health Care","volume":" ","pages":"e35"},"PeriodicalIF":2.6000,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11569914/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Technology Assessment in Health Care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1017/S026646232400031X","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: Rare diseases (RD)-related policies have received significant attention due to the pressing medical requirements associated with these medical conditions and the substantial impact and treatments they may have on healthcare budgets. Nevertheless, policymakers frequently encounter difficulties in managing issues concerning resource allocation and prioritization within this population. Realizing the need to address such problems, this study was conducted to develop a framework based on the multicriteria decision analysis to improve RD reimbursement prioritization in Malaysia.

Methods: Primarily, a scoping review was performed to identify the methods and criteria used for the reimbursement of RD treatment, followed by strategic stakeholder engagement and a deliberative process on determining the best approach for the framework, including criteria identification, elicitation of weights, and a pilot assessment using the framework.

Results: The findings reflected the priorities and perspectives of the stakeholders, which identified eight key criteria and their associated weights, namely effectiveness (19.6 percent), disease severity (15.6 percent), safety (14.2 percent), access to treatment (12.6 percent), economic consideration (12.2 percent), type of therapeutic treatment (11.5 percent), availability of alternatives (8.3 percent), and population group (6 percent).

Conclusions: In summary, the developed framework was well-accepted by the Rare Disease Committee, which will be applied as part of the committee deliberation for transparent and equitable decision making on fund allocation and reimbursement of orphan and RD treatment in Malaysia.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
为马来西亚罕见病报销优先顺序制定 MCDA 框架。
目的:与罕见病(RD)相关的政策受到了极大关注,因为这些医疗条件具有迫切的医疗需求,而且可能对医疗预算产生重大影响和治疗效果。然而,政策制定者在管理该人群的资源分配和优先次序问题上经常遇到困难。认识到解决这些问题的必要性,本研究以多标准决策分析为基础制定了一个框架,以改善马来西亚的研发报销优先顺序:方法:首先进行了范围审查,以确定 RD 治疗报销所使用的方法和标准,然后进行战略利益相关者参与和审议过程,以确定框架的最佳方法,包括确定标准、征求权重和使用框架进行试点评估:结果:研究结果反映了利益相关者的优先事项和观点,确定了八项关键标准及其相关权重,即有效性(19.6%)、疾病严重程度(15.6%)、安全性(14.2%)、获得治疗的机会(12.6%)、经济考虑(12.2%)、治疗类型(11.5%)、替代品的可用性(8.3%)和人群(6%):总之,所制定的框架得到了罕见病委员会的广泛认可,该框架将作为委员会审议工作的一部分,为马来西亚孤儿和罕见病治疗的资金分配和报销提供透明、公平的决策依据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
International Journal of Technology Assessment in Health Care
International Journal of Technology Assessment in Health Care 医学-公共卫生、环境卫生与职业卫生
CiteScore
4.40
自引率
15.60%
发文量
116
审稿时长
6-12 weeks
期刊介绍: International Journal of Technology Assessment in Health Care serves as a forum for the wide range of health policy makers and professionals interested in the economic, social, ethical, medical and public health implications of health technology. It covers the development, evaluation, diffusion and use of health technology, as well as its impact on the organization and management of health care systems and public health. In addition to general essays and research reports, regular columns on technology assessment reports and thematic sections are published.
期刊最新文献
Implementation of the EU's Health Technology Assessment regulation: where does existing methods guidance require concretization and what are the relevant methodological options? Driving Policy Dialogue on Health Technology Assessment in Eastern Europe and Central Asia: reporting from an initiative of Health Technology Assessment International. PATIENT PERSPECTIVES ON CONTINUOUS GLUCOSE MONITORING SYSTEM (CGMS) FOR DIABETES IN MALAYSIA: A VITAL VOICE IN HEALTH TECHNOLOGY ASSESSMENT (HTA) INFORMING DECISION-MAKING. Celebrating 30 years of the international network of agencies for health technology assessment (INAHTA). A minimum dataset for destination therapy with left ventricular assist device: the evidence that matters to decision makers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1